Trump has rolled back many of his steepest tariffs over recent months, including a sky-high levy on China, the top source of ...

President Trump is readying plans for industry-specific tariffs to kick in alongside his country-by-country duties in two ...

Sino Biopharm will buy the 95.1 percent of the Chinese developer of novel biologic drugs for cancer treatment that it does not already own, the Beijing-based company announced late on July 15. LaNova ...

Biotech deals involving assets developed in China are surging, a Jefferies report shows. | Biotech deals involving assets ...

Both Eli Lilly LLY and Merck MRK are major players in the U.S. pharmaceutical industry, developing and commercializing ...

A promising experimental drug is one more sign of the impending disruption the booming Chinese biotech industry could bring ...

Merck & Co., Inc. outshines Gilead Sciences, Inc. with stronger dividend growth, valuation metrics & PEGY ratio. Click for ...

An obesity drug from Hengrui Pharma and Kailera Therapeutics succeeded in a late-stage trial in China, while Anne Wojcicki’s ...

Today’s Forbes Daily covers potential Federal Reserve chair replacements, the wealthiest get richer off bitcoin, a new ...

Michelle Xia gained experience at U.S. pharmaceutical firms before launching her own biotech company back home in China. In a ...

Bristol Myers Squibb BMY announced a strategic collaboration agreement with BioNTech BNTX for the global co-development and ...

Private equity work is up year-over-year, but tariffs, inflation and valuations continue to be an issue for dealmakers.